Vinpotropil: vinpocetine plus piracetam — EA009666B1
Authors not yet confirmed · 2008 · EA009666B1 · patent family 34545985
Published 2008-02-28.
Reported patent results
Reported findings
The patent reports improvement in anxiety and selected attention/symptom measures, with neutral depression comparisons.
Early post-ischemic-stroke comparison of fixed-combination Vinpotropil with vinpocetine, piracetam and separately combined ingredients; assessments at baseline and day 21.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Anxiety score | Vinpotropil 32.7 → 17.6; other displayed groups 30.1 → 26.5, 30.0 → 22.3 and 31.5 → 24.7 | Spielberger score; before/after significance is not a verified between-group treatment effect · 21 days |
| Depression score | Vinpotropil 21.1 → 20.2; no significant differences reported in any group | Neutral depression result retained · 21 days |
| Withdrawals and gastric symptoms | 2 main-group and 6 comparator-group exclusions; gastric/dyspeptic complaints reported in 5% fixed-combination versus 20% separate-combination group | Group denominators and analysis of withdrawals need original-trial verification |
Unclear allocation, co-treatment and incomplete group reporting prevent proof of synergy or superiority of the fixed formulation. These patent observations may overlap the clinical literature.
Source for the extracted data ↗ · Checked 2026-11-06
Patent claims and provenance
Formulation. The patent describes the combination composition containing vinpocetine and piracetam.
A fixed-combination claim does not establish either ingredient's independent effect or demonstrate pharmacological synergy.
- Publication
- EA009666B1 ↗ · 2008-02-28
- Earliest priority / filing
- 2003-11-03 / 2004-10-29
- Original applicant / assignee
- Закрытое Акционерное Общество "Канонфарма Продакшн"
- Indexed status
- Not shown; official status unverified · checked 2026-11-06
- Patent family
- 34545985 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Pharmaceutical composition exhibiting a cerebral vasodilatation and nootropic activity
Inventors: Not established from accessed metadata.
Molekul summary of the linked publication. Educational information, not medical advice. Seek qualified healthcare help for medical conditions.
Methods, limitations & source review
Study limitations
- A fixed-combination claim does not establish either ingredient's independent effect or demonstrate pharmacological synergy.
- Unclear allocation, co-treatment and incomplete group reporting prevent proof of synergy or superiority of the fixed formulation. These patent observations may overlap the clinical literature.
- Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
- Status labels are Google Patents index snapshots for the displayed publication or application; the record gives its source-check date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Document format: Original patent text and indexed metadata
Review depth: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.
Related-report group: patent-family-34545985. Reports in this group are not assumed to be independent trials.
Source access and review scope
Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Recorded source-check date: 2026-11-06. This date does not imply a completed systematic review.
Source type: Patent publication
Citation and original source
Original source: Author unconfirmed. Vinpotropil: vinpocetine plus piracetam — EA009666B1 EA009666B1 · patent family 34545985 2008.
Molekul research summary: https://molekul.io/research/patent-ea009666b1. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entryRelated compound profiles
Vinpotropil
A fixed piracetam–vinpocetine preparation used as a nonpeptide comparator in the 2007 environmental-chamber study.
Piracetam
Piracetam, marketed as Nootropil, connects the original nootropic concept with Soviet clinical adoption and later operator, hypoxia and maritime research. Healthy-volunteer experiments, clinical reviews and combination proposals answer different questions.